EpiCast Report: Sjgrens Syndrome - Epidemiology Forecast to 2024
Sjgrens syndrome (SS) is a chronic systemic autoimmune disease characterized by chronic inflammation of the exocrine glands and is one of the three most common autoimmune diseases in the US. Due to the lack of validated and universally accepted diagnostic criteria for diagnosing SS, a large variation can be seen in the rates of this disease. The three most commonly utilized diagnostic criteria for SS include the Copenhagen criteria, the European classification criteria, and the International Collaborative Clinical Alliances Cohort (SICCA) criteria. The European classification criteria, which were revised by the American-European Consensus Group (AECG), are currently the most widely used diagnostic criteria. Even though no cure currently exists for SS, treatments are used to manage the symptoms and prevent further complications. These might include the use of salivary substitutes and artificial tears, or in the case of secondary SS, treatment of the underlying disease.
GlobalData epidemiologists estimate that within the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, Japan), as shown in Figure 1, the diagnosed prevalent cases of SS will increase from 3,210,390 cases in 2014 to 3,533,298 cases in 2024, at an Annual Growth Rate (AGR) of 1.01% over the forecast period. Throughout the forecast period, the US will have the highest number of diagnosed prevalent cases of SS in the 7MM. Similarly, the diagnosed prevalent cases of primary Sjgrens syndrome (pSS) will increase from 2,161,973 cases in 2014 to 2,384,551 cases in 2024, while the diagnosed prevalent cases of secondary Sjgrens syndrome (sSS) will increase from 1,048,417 cases in 2014 to 1,148,874 cases in 2024. During the forecast period, the proportion of ocular manifestations in the diagnosed prevalent cases of SS will range from a low of 87.00% in the UK and the US to a high of 98.00% in Italy. Similarly, approximately, 93.00-96.00% of prevalent SS cases will experience oral symptoms during the forecast period.
- The Sjgrens Syndrome (SS) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for SS, which includes both primary Sjgrens syndrome (pSS) and secondary Sjgrens syndrome (sSS), in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of pSS, segmented by sex and age (from 18-19 years, then in 10-year age groups), diagnosed prevalent cases of sSS as well as SS and cases of ocular and oral manifestations in SS, in these markets.
- The SS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy
The SS EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global SS market.
- Quantify patient populations in the global SS market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for SS therapeutics in each of the markets covered.
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
2.3 Upcoming Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 10
3.3 Global Trends 12
3.3.1 7MM Diagnosed Prevalent Cases 14
3.3.2 5EU Diagnosed Prevalent Cases 15
3.3.3 Japan Diagnosed Prevalent Cases 15
3.4 Forecast Methodology 15
3.4.1 Sources Used 19
3.4.2 Sources Not Used 21
3.4.3 Forecast Assumptions and Methods 22
3.5 Epidemiological Forecast for SS (2014-2024) 26
3.5.1 Diagnosed Prevalent Cases of SS 26
3.5.2 Age-Specific Diagnosed Prevalent Cases of pSS 32
3.5.3 Sex-Specific Diagnosed Prevalent Cases of pSS 34
3.5.4 Age-Standardized Diagnosed Prevalence of pSS 36
3.5.5 Ocular and Oral Manifestations 38
3.6 Discussion 39
3.6.1 Epidemiological Forecast Insight 39
3.6.2 Limitations of the Analysis 41
3.6.3 Strengths of the Analysis 41
4 Appendix 43
4.1 Bibliography 43
4.2 About the Authors 47
4.2.1 Epidemiologists 47
4.2.2 Reviewers 47
4.2.3 Global Director of Therapy Analysis and Epidemiology 49
4.2.4 Global Head of Healthcare 49
4.3 About GlobalData 50
4.4 About EpiCast 50
4.5 Disclaimer 51
1.1 List of Tables
Table 1: Risk Factors and Comorbidities for SS 11
Table 2: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of pSS 16
Table 3: 7MM, Sources Used to Forecast the Oral and Ocular Manifestations of SS 17
Table 4: 7MM, Sources Not Used in the Epidemiological Analysis of SS 22
Table 5: Diagnosed Prevalent Cases of SS, Age 18 Years, Both Sexes, N, 2014-2024 31
Table 6: 7MM, Age-Specific Diagnosed Prevalent Cases of pSS, Age 18 Years, Both Sexes, N, 2014 33
Table 7: 7MM, Sex-Specific Diagnosed prevalent Cases of pSS, Age 18 Years, N, 2014 35
1.2 List of Figures
Figure 1: Diagnosed Prevalence Rate of SS in the 7MM, 2014 14
Figure 2: Case Flow Map for pSS: US, Germany, Italy, UK, and Japan 18
Figure 3: Case Flow Map for pSS: France and Spain 19
Figure 4: 7MM, Diagnosed Prevalent Cases of pSS, Age 18 Years, Both Sexes, N, Selected Years, 2014-2024 27
Figure 5: 7MM, Diagnosed Prevalent Cases of sSS, Age 18 Years, Both Sexes, N, Selected Years, 2014-2024 29
Figure 6: 7MM Diagnosed Prevalent Cases of SS, Age 18 Years, Both Sexes, N, Selected Years, 2014-2024 32
Figure 7: 7MM, Age-Specific Diagnosed Prevalent Cases of pSS, Age 18 Years, Both Sexes, N, 2014 34
Figure 8: 7MM, Sex-Specific Diagnosed Prevalent Cases of pSS, Age 18 Years, N, 2014 36
Figure 9: 7MM, Age-Standardized Diagnosed Prevalence of pSS, Age 18 Years , 2014 37
Figure 10: 7MM, Ocular and Oral Manifestations of SS in the Diagnosed Prevalent Cases of SS, Age 18 Years , 2014 39
Make an enquiry before buying this Report
Please fill the enquiry form below.